PSTX Quote, Financials, Valuation and Earnings

Galectin Therapeutics has a net margin of 28.2% compared to Poseida Therapeutics's net margin of --. Poseida Therapeutics's return on equity of -66.05% beat Galectin Therapeutics's return on equity of --.

Poseida Therapeutics has a consensus price target of $14.00, signalling upside risk potential of 0.11%. On the other hand Galectin Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1208.59%. Given that Galectin Therapeutics has higher upside potential than Poseida Therapeutics, analysts believe Galectin Therapeutics is more attractive than Poseida Therapeutics.

Poseida Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Galectin Therapeutics has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.07%.

Poseida Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galectin Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Poseida Therapeutics pays -- of its earnings as a dividend. Galectin Therapeutics pays out -- of its earnings as a dividend.

Poseida Therapeutics quarterly revenues are $71.7M, which are larger than Galectin Therapeutics quarterly revenues of --. Poseida Therapeutics's net income of $20.2M is higher than Galectin Therapeutics's net income of -$11.2M. Notably, Poseida Therapeutics's price-to-earnings ratio is -- while Galectin Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Poseida Therapeutics is 6.09x versus -- for Galectin Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Phathom Pharmaceuticals has a net margin of 28.2% compared to Poseida Therapeutics's net margin of -523.34%. Poseida Therapeutics's return on equity of -66.05% beat Phathom Pharmaceuticals's return on equity of --.

Poseida Therapeutics has a consensus price target of $14.00, signalling upside risk potential of 0.11%. On the other hand Phathom Pharmaceuticals has an analysts' consensus of $22.00 which suggests that it could grow by 231.43%. Given that Phathom Pharmaceuticals has higher upside potential than Poseida Therapeutics, analysts believe Phathom Pharmaceuticals is more attractive than Poseida Therapeutics.

Poseida Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Phathom Pharmaceuticals has a beta of 0.562, suggesting its less volatile than the S&P 500 by 43.812%.

Poseida Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phathom Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Poseida Therapeutics pays -- of its earnings as a dividend. Phathom Pharmaceuticals pays out -- of its earnings as a dividend.

Poseida Therapeutics quarterly revenues are $71.7M, which are larger than Phathom Pharmaceuticals quarterly revenues of $16.4M. Poseida Therapeutics's net income of $20.2M is higher than Phathom Pharmaceuticals's net income of -$85.6M. Notably, Poseida Therapeutics's price-to-earnings ratio is -- while Phathom Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Poseida Therapeutics is 6.09x versus 17.05x for Phathom Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of 28.2% compared to Poseida Therapeutics's net margin of -63.65%. Poseida Therapeutics's return on equity of -66.05% beat Revance Therapeutics's return on equity of --.

Poseida Therapeutics has a consensus price target of $14.00, signalling upside risk potential of 0.11%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 147.96%. Given that Revance Therapeutics has higher upside potential than Poseida Therapeutics, analysts believe Revance Therapeutics is more attractive than Poseida Therapeutics.

Poseida Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.478%.

Poseida Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Poseida Therapeutics pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

Poseida Therapeutics quarterly revenues are $71.7M, which are larger than Revance Therapeutics quarterly revenues of $59.9M. Poseida Therapeutics's net income of $20.2M is higher than Revance Therapeutics's net income of -$38.1M. Notably, Poseida Therapeutics's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Poseida Therapeutics is 6.09x versus 1.16x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of 28.2% compared to Poseida Therapeutics's net margin of -788.06%. Poseida Therapeutics's return on equity of -66.05% beat Sage Therapeutics's return on equity of -48.2%.

Poseida Therapeutics has a consensus price target of $14.00, signalling upside risk potential of 0.11%. On the other hand Sage Therapeutics has an analysts' consensus of $24.39 which suggests that it could grow by 64.23%. Given that Sage Therapeutics has higher upside potential than Poseida Therapeutics, analysts believe Sage Therapeutics is more attractive than Poseida Therapeutics.

Poseida Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.067%.

Poseida Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Poseida Therapeutics pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Poseida Therapeutics quarterly revenues are $71.7M, which are larger than Sage Therapeutics quarterly revenues of $11.9M. Poseida Therapeutics's net income of $20.2M is higher than Sage Therapeutics's net income of -$93.6M. Notably, Poseida Therapeutics's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Poseida Therapeutics is 6.09x versus 3.11x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.